Rafferty Asset Management
KYMR icon

Rafferty Asset Management’s Kymera Therapeutics KYMR Stock Holding History

Rafferty Asset Management’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.05M Sell
35,287
-20,044
-36% -$1.72M 0.01% 415
2026
Q1 		$4.61M Sell
55,331
-3,322
-6% -$263K 0.02% 409
2025
Q4 		$4.56M Sell
58,653
-9,642
-14% -$651K 0.02% 449
2025
Q3 		$3.87M Buy
68,295
+28,157
+70% +$1.27M 0.01% 490
2025
Q2 		$1.75M Sell
40,138
-18,844
-32% -$649K 0.01% 635
2025
Q1 		$1.61M Buy
58,982
+2,104
+4% +$76.7K 0.01% 625
2024
Q4 		$2.29M Sell
56,878
-8,573
-13% -$387K 0.01% 617
2024
Q3 		$3.1M Sell
65,451
-25,369
-28% -$1.12M 0.01% 530
2024
Q2 		$2.71M Sell
90,820
-120,041
-57% -$4.16M 0.01% 558
2024
Q1 		$8.48M Buy
210,861
+90,672
+75% +$3.24M 0.03% 332
2023
Q4 		$3.06M Sell
120,189
-29,910
-20% -$535K 0.01% 551
2023
Q3 		$2.09M Sell
150,099
-64,391
-30% -$1.29M 0.01% 600
2023
Q2 		$4.93M Buy
214,490
+5,401
+3% +$155K 0.03% 415
2023
Q1 		$6.2M Sell
209,089
-6,486
-3% -$209K 0.04% 337
2022
Q4 		$5.38M Buy
215,575
+35,933
+20% +$958K 0.05% 361
2022
Q3 		$3.91M Buy
179,642
+29,303
+19% +$772K 0.04% 376
2022
Q2 		$2.96M Buy
150,339
+26,211
+21% +$612K 0.03% 396
2022
Q1 		$5.25M Buy
124,128
+28,352
+30% +$1.2M 0.03% 379
2021
Q4 		$6.08M Buy
95,776
+49,027
+105% +$2.86M 0.03% 295
2021
Q3 		$2.75M Sell
46,749
-4,852
-9% -$281K 0.02% 531
2021
Q2 		$2.5M Sell
51,601
-209
-0.4% -$9.07K 0.02% 597
2021
Q1 		$2.01M Buy
+51,810
New +$3.12M 0.01% 625

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Rafferty Asset Management's KYMR Position: Q2 2026 in Review

Rafferty Asset Management reduced its Kymera Therapeutics (KYMR) stake by 36% in Q2 2026, selling an estimated $1.72M and leaving 35,287 shares worth $4.05M. The position accounts for 0.01% of the portfolio, ranked #415.

Rafferty Asset Management first reported a position in KYMR in Q1 2021 and has held it in 22 quarters since. The position peaked at $8.48M in Q1 2024. 275 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • Rafferty Asset Management held 35,287 shares of Kymera Therapeutics worth $4.05M as of Q2 2026.
  • Rafferty Asset Management sold 20,044 Kymera Therapeutics shares in Q2 2026, an estimated $1.72M.
  • Kymera Therapeutics made up 0.01% of Rafferty Asset Management's portfolio in Q2 2026, its #415 holding.
  • Rafferty Asset Management first reported a position in Kymera Therapeutics in Q1 2021 and has held it in 22 quarters since.
  • Rafferty Asset Management's Kymera Therapeutics position peaked at $8.48M in Q1 2024.
  • 275 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Rafferty Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.